Revenue: As of FY2026 Q1, the actual value is USD 0.EBIT: As of FY2026 Q1, the actual value is USD -90.38 M.<h4>Financial Position (as of March 31, 2026)</h4>Kailera Therapeutics, Inc. reported total cash, cash equivalents, and marketable securities of $581.9 million as of March 31, 2026, which included $718.8 million in gross proceeds from its initial public offering . Cash and cash equivalents were $111.8 million as of March 31, 2026, a decrease from $160.3 million as of December 31, 2025 . Marketable securities increased to $407.3 million as of March 31, 2026, from $385.8 million as of December 31, 2025 .Total current assets were $530.3 million as of March 31, 2026, down from $557.5 million as of December 31, 2025 . Total assets decreased to $624.8 million as of March 31, 2026, from $692.3 million as of December 31, 2025 . Total current liabilities rose to $54.8 million as of March 31, 2026, from $46.4 million as of December 31, 2025 . Total liabilities increased to $64.5 million as of March 31, 2026, from $56.4 million as of December 31, 2025 . The accumulated deficit was - $447.5 million as of March 31, 2026, compared to - $368.7 million as of December 31, 2025 .<h4>Operating Expenses (Three Months Ended March 31)</h4>Research and Development (R&amp;D) expenses for Kailera Therapeutics, Inc. were $70.9 million for the first quarter of 2026, a significant increase from $10.1 million for the same period in 2025 . This $60.7 million increase was primarily due to growth in product candidate development, including nonclinical, clinical, and contract manufacturing costs, and higher personnel-related costs . General and Administrative (G&amp;A) expenses were $13.8 million for the first quarter of 2026, up from $10.3 million for the same period in 2025 . This $3.5 million increase was mainly attributed to personnel-related costs and professional service costs as the company expanded its operations . Total operating expenses for the first quarter of 2026 were $84.7 million, compared to $20.5 million for the same period in 2025 .<h4>Net Loss (Three Months Ended March 31)</h4>Kailera Therapeutics, Inc. reported a loss from operations of - $84.7 million for the first quarter of 2026, compared to - $20.5 million for the same period in 2025 . Interest income increased to $5.7 million for the first quarter of 2026, from $1.7 million for the same period in 2025 . Other income, net, was $0.1 million for the first quarter of 2026, down from $0.8 million for the same period in 2025 . Total other income was $5.8 million for the first quarter of 2026, compared to $2.5 million for the same period in 2025 . The net loss for Kailera Therapeutics, Inc. was - $78.9 million for the first quarter of 2026, compared to a net loss of - $18.0 million for the first quarter of 2025 .<h4>Outlook / Guidance</h4>Kailera Therapeutics, Inc. anticipates that its cash on hand, including proceeds from its initial public offering, will fund operations into mid-2028 . Key milestones include U.S. Phase 2b high dose obesity data for ribupatide injection in 2027 and global Phase 3 obesity data in 2028 . The company plans to initiate global Phase 3 obesity trials for ribupatide oral as early as the first half of 2027, with global Phase 2 obesity data for KAI-7535 and Phase 1 trial data for KAI-4729 also expected in 2027 .

Kailera Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0